A Phase 1 Study of ABBV-787 in People With Acute Myeloid Leukemia

Full Title

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV 787 in Adult Subjects with Acute Myeloid Leukemia (AML)

Purpose

Researchers want to find the best dose of ABBV-787 to treat people with leukemia. The people in this study have acute myeloid leukemia (AML) that keeps growing even after treatment.

ABBV-787 targets cells that have the CD33 protein, which plays a role in cancer cell growth. By destroying these cells, ABBV-787 may help slow or stop the growth of your cancer. ABBV-787 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have AML that came back or keeps growing after treatment.
• Not have had more than 3 prior regimens of AML therapy.
• Have completed previous anti-cancer treatments at least 2 weeks before taking ABBV-787.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.